Shopping Cart
- Remove All
- Your shopping cart is currently empty
BCL6-IN-8c is an orally active and potent inhibitor of B-cell lymphoma 6 (BCL6)-corepressor interaction(IC50 of 0.10 μM in cell-free enzyme-linked immunosorbent assay).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $970 | 5 days |
Description | BCL6-IN-8c is an orally active and potent inhibitor of B-cell lymphoma 6 (BCL6)-corepressor interaction(IC50 of 0.10 μM in cell-free enzyme-linked immunosorbent assay). |
Targets&IC50 | BCL6-corepressor interaction:0.10 μM |
In vitro | BCL6-IN-8c (Compound 8c) exhibits good cellular PPI inhibitory activity in the submicromolar range (M2H IC50 = 0.72 μM). BCL6-IN-8c can not exhibit significant cytotoxicity even at 30 μM[1]. |
In vivo | BCL6-IN-8c exhibits a good pharmacokinetic profile (Cmax = 233 ng/mL, Tmax = 2 hours, MRT = 3.3 h, AUC = 1.27 mg?h/mL, F (oral bioavailability) = 79.9%)[1]. The pharmacokinetic profile of BCL6-IN-8c (Compound 8c) is evaluated by a mouse cassette-dosing study (0.1 mg/kg iv; 1 mg/kg po). |
Molecular Weight | 417.84 |
Formula | C20H20ClN3O5 |
Cas No. | 2130878-25-8 |
Relative Density. | 1.410 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.